Skip to Main Content

Iovance Biotherapeutics, Inc. Common Stock

IOVA Real Time Price USD
2.01
+0.13
(6.95%)
As of today at 16:48 UTC-04:00 (Market Closed)
Add to Watchlist
Overview
Financials
Forecast
Insiders
Institutions
Government
Ownership
News
Income
Balance Sheet
Cash Flow
Revenue Breakdown

Recent trades of IOVA by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
IOVA Stock Insider Trading Activity Follow @QuiverQuant for major insider updates
Closing Price
Purchase
Sale
Name
Type
Shares
Price
Shares Held
Date
Reported
IOVA Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
IOVA Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported

Recently reported changes by institutional investors

Whales2.666666667New0Increased1Held2Decreased1Closed4

Quarterly net insider trading by IOVA's directors and management

2024Q32024Q42025Q12025Q22025Q3−40k−20k020k40k
Net Shares Purchased by Insiders

* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.

About

Backtest Start Date
CAGR (Total)
Return (30d)
Return (1Y)
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • MAX

About

Backtest Start Date

Key Metrics

Return (1d)

Return (30d)

Return (1Y)

CAGR (Total)

Max Drawdown

Beta

Alpha

Sharpe Ratio

Win Rate

Average Win

Average Loss

Annual Volatility

Annual Std Dev

Information Ratio

Treynor Ratio

Total Trades

Show More
Metrics Definitions
  • Alpha

    Measures a portfolio's risk-adjusted performance against that of its benchmark

    Learn More
  • Annual Standard Deviation

    Measures how much the portfolio's total return varies from its mean or average.

    Learn More
  • Annual Volatility

    A statistical measure of the dispersion of returns for the portfolio.

    Learn More
  • Average Win

    The average return (%) for trades that resulted in a positive return.

  • Average Loss

    The average return (%) for trades that resulted in a negative return.

  • Beta

    A measure of the volatility of the portfolio compared to the market as a whole.

    Learn More
  • CAGR

    CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.

    Learn More
  • Information Ratio

    A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.

    Learn More
  • Max Drawdown

    the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.

    Learn More
  • Sharpe Ratio

    The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.

    Learn More
  • Total Trades

    The total number of trades made by this strategy.

  • Treynor Ratio

    Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.

    Learn More
  • Win Rate

    The percentage of total trades that resulted in a positive return.

Subscribe to Quiver Premium for insider trading alerts

Be the first to see our newest insights and key updates across all datasets.

schema-2

Government lobbying spending instances

  • $260,000 Jan 20, 2023 Issue: Medicare/Medicaid Health Issues
  • $260,000 Oct 11, 2022 Issue: Medicare/Medicaid Health Issues
  • $260,000 Jul 20, 2022 Issue: Medicare/Medicaid Health Issues
  • $50,000 Apr 20, 2022 Issue: Medicare/Medicaid
  • $50,000 Apr 19, 2022 Issue: Health Issues
  • $50,000 Jan 20, 2022 Issue: Health Issues
  • $50,000 Jan 19, 2022 Issue: Medicare/Medicaid
  • $50,000 Oct 20, 2021 Issue: Medicare/Medicaid
  • $50,000 Oct 20, 2021 Issue: Health Issues
  • $50,000 Jul 20, 2021 Issue: Medicare/Medicaid
  • $50,000 Jul 19, 2021 Issue: Health Issues
  • $40,000 Apr 20, 2021 Issue: Medicare/Medicaid
  • $40,000 Apr 19, 2021 Issue: Health Issues
  • $30,000 Jan 21, 2021 Issue: Medicare/Medicaid
  • $30,000 Jan 19, 2021 Issue: Health Issues

Estimated quarterly lobbying spending

202120220200k400k600k800k
Q4Q3Q2Q1Lobbying Amount

IOVA Revenue by Segment or Geography

By Segment
By Geography
Quiver Logo

No Revenue by Segment data for this ticker

Revenue Breakdown Dashboard
Quiver Logo

No Revenue by Geography data for this ticker

Revenue Breakdown Dashboard
IOVA Income Statement
IOVA Balance Sheet
IOVA Cash Flow
U.S. Patents

New patents grants

  • Patent Title: Remnant tumor infiltrating lymphocytes and methods of preparing and using the same Feb. 25, 2025
  • Patent Title: Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy Feb. 18, 2025
  • Patent Title: Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy Feb. 18, 2025
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Feb. 18, 2025
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Jan. 14, 2025
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Jan. 07, 2025
  • Patent Title: Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy Dec. 17, 2024
  • Patent Title: Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy Dec. 03, 2024
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Oct. 22, 2024
  • Patent Title: Processes for generating til products enriched for tumor antigen-specific t-cells Oct. 01, 2024
  • Patent Title: Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy Jul. 09, 2024
  • Patent Title: Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy Jul. 02, 2024
  • Patent Title: Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof Jul. 02, 2024
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Jun. 04, 2024
  • Patent Title: Til expansion processes using specific cytokine combinations and/or akti treatment May. 14, 2024
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes May. 07, 2024
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Apr. 30, 2024
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Mar. 26, 2024
  • Patent Title: Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy Jan. 09, 2024
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Jan. 09, 2024
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Jan. 02, 2024
  • Patent Title: Methods of using tumor infiltrating lymphocytes in double-refractory melanoma Nov. 21, 2023
  • Patent Title: Processes for generating til products enriched for tumor antigen-specific t-cells Aug. 01, 2023
  • Patent Title: Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion Jun. 06, 2023
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy May. 16, 2023
  • Patent Title: Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy Apr. 18, 2023
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Jan. 03, 2023
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Dec. 20, 2022
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Dec. 06, 2022
  • Patent Title: Methods of using tumor infiltrating lymphocytes in double-refractory melanoma Sep. 06, 2022
  • Patent Title: Remnant tumor infiltrating lymphocytes and methods of preparing and using the same Aug. 02, 2022
  • Patent Title: Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy Jul. 12, 2022
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Jun. 28, 2022
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Jun. 21, 2022
  • Patent Title: Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof Jun. 14, 2022
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Jun. 07, 2022
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Jun. 07, 2022
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes May. 31, 2022
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes May. 31, 2022
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy May. 31, 2022
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy May. 24, 2022
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Apr. 26, 2022
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Apr. 19, 2022
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Apr. 19, 2022
  • Patent Title: Remnant tumor infiltrating lymphocytes and methods of preparing and using the same Apr. 05, 2022
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Apr. 05, 2022
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Mar. 15, 2022
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Mar. 15, 2022
  • Patent Title: Restimulation of cryopreserved tumor infiltrating lymphocytes Mar. 08, 2022
  • Patent Title: Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy Feb. 22, 2022
Government Contracts

Estimated quarterly amount awarded from public contracts

20242025050k100k150k200k
Q4Q3Q2Q1Government Contracts Amount
IOVA News

Recent insights relating to IOVA

CNBC Recommendations

Recent picks made for IOVA stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in IOVA

IOVA Analyst Ratings

IOVA Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
IOVA Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $IOVA stock a Buy, Sell, or Hold?

  • What is the price target for $IOVA stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

IOVA Top Shareholders
Shareholder
Shares Held
IOVA Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $IOVA stock?

  • Who owns the most shares of $IOVA stock?

  • What funds own $IOVA stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

IOVA Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view IOVA Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top